News Novo Nordisk A/S Börse Stuttgart

Equities

NOV

DK0062498333

Market Closed - Börse Stuttgart Other stock markets 17:26:05 28/06/2024 BST			5-day change	1st Jan Change
134.6 ^EUR	+0.13%		+1.23%	+44.11%

06-28	India plans incentives for diabetes, obesity drug makers in 2026, government official says	RE
06-28	NOVO NORDISK : UBS gives a Neutral rating	ZD

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

India plans incentives for diabetes, obesity drug makers in 2026, government official says	06-28	RE
NOVO NORDISK : UBS gives a Neutral rating	06-28	ZD
European Equities Close Mostly Lower Thursday; Bank of England Warns of 'Sharp Correction' Risk	06-27	MT
Top Midday Stories: Walgreens Shares Tumble on Lower Guidance, Store Closures; SM Energy, NOG to Buy XCL Resources; Uber, Lyft Worker Classification Heads to Massachusetts Ballot	06-27	MT
Novo Nordisk to Limit Launch of Wegovy in China, Executive Says	06-27	MT
NOVO NORDISK : JP Morgan gives a Buy rating	06-27	ZD
The same old winners	06-27
NOVO NORDISK : Goldman Sachs reiterates its Buy rating	06-27	ZD
2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours	06-26	MT
2seventy Bio Sells Gene Editing Therapy To Novo Nordisk for Up To $40 Million	06-26	DJ
Sector Update: Health Care Stocks Softer Late Afternoon	06-26	MT
Sector Update: Health Care Stocks Lower in Afternoon Trading	06-26	MT
Sector Update: Health Care	06-26	MT
European Equities Close Lower in Wednesday Trading	06-26	MT
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment	06-26	MT
Novo Nordisk to Take $816.2 Million Impairment Loss After Stopping Clarion-CKD Trial	06-26	MT
Novo Nordisk Halts Late-stage Hypertension, Kidney Disease Treatment Trial; DKK6 Billion Impairment Loss Expected	06-26	MT
Novo Nordisk: trial failure and impact on results	06-26	CF
Novo Nordisk to Take $816.2 Million Impairment Loss After Stopping Clarion-CKD Trial	06-26	MT
Novo Nordisk to Take $816 Million Impairment Charge After Stopping Clarion-CKD Trial	06-26	MT